Positions

Selected Publications

Academic Article

Year Title Altmetric
2022 Deletion in chromosome 6 spanning alpha-synuclein and multimerin1 loci in the Rab27a/b double knockout mouseScientific Reports.  12. 2022
2022 Pathological α-synuclein recruits LRRK2 expressing pro-inflammatory monocytes to the brainMolecular Neurodegeneration.  17. 2022
2022 Fostering a diverse regional community of physician-scientist traineesJournal of the National Medical Association.  114:251-257. 2022
2022 14-3-3θ Does Not Protect against Behavioral or Pathological Deficits in Alzheimer’s Disease Mouse ModelseNeuro.  9. 2022
2022 Image Quantification for TSPO PET with a Novel Image-Derived Input Function MethodDiagnostics.  12. 2022
2022 A novel curricular framework to develop grant writing skills among MD-PhD studentsJournal of Clinical and Translational Science.  6. 2022
2022 Mutant glucocerebrosidase impairs α-synuclein degradation by blockade of chaperone-mediated autophagyScience Advances.  8. 2022
2022 The S-Factor, a New Measure of Disease Severity in Spinocerebellar Ataxia: Findings and Implications 2022
2021 14-3-3 mitigates alpha-synuclein aggregation and toxicity in the in vivo preformed fibril modelActa Neuropathologica Communications.  9. 2021
2021 Pathways to Parkinson’s disease: a spotlight on 14-3-3 proteinsnpj Parkinson's Disease.  7. 2021
2021 Sex-based differences in the activation of peripheral blood monocytes in early Parkinson diseasenpj Parkinson's Disease.  7. 2021
2021 14-3-3 Proteins: Novel Pharmacological Targets in Neurodegenerative DiseasesTrends in Pharmacological Sciences.  42:226-238. 2021
2020 14-3-3 mitigates alpha-synuclein aggregation and toxicity in the in vivo preformed fibril model 2020
2020 007 (x2)-3-3: 14-3-3 Targeted Compounds as Double AgentsTrends in Pharmacological Sciences.  41:431-433. 2020
2020 The GTPase Rab27b regulates the release, autophagic clearance, and toxicity of alpha-synucleinJournal of Biological Chemistry.  295:8005-8016. 2020
2018 Primary Bone Marrow Diffuse Large B-cell Lymphoma Presenting as Transverse MyelitisAmerican Journal of the Medical Sciences.  356:561-566. 2018
2018 14-3-3 proteins reduce cell-to-cell transfer and propagation of pathogenic α-synuclein 2018
2017 Dysregulation of 14-3-3 proteins in neurodegenerative diseases with Lewy body or Alzheimer pathologyAnnals of Clinical and Translational Neurology.  4:466-477. 2017
2017 Disparate genes come together: Spatial and genetic screens point to disruptions in vesicle trafficking and mRNA metabolism in synucleinopathiesMovement Disorders.  32:840. 2017
2016 14-3-3 Proteins regulate mutant LRRK2 kinase activity and neurite shorteningHuman Molecular Genetics.  25:109-122. 2016
2016 CoQ10 in progressive supranuclear palsy: A randomized, placebo-controlled, double-blind trial 2016
2015 14-3-3 inhibition promotes dopaminergic neuron loss and 14-3-3θ overexpression promotes recovery in the MPTP mouse model of Parkinson's diseaseNeuroscience.  307:73-82. 2015
2015 Increased 14-3-3 phosphorylation observed in Parkinson's disease reduces neuroprotective potential of 14-3-3 proteinsNeurobiology of Disease.  79:1-13. 2015
2014 Reaping what you sow: Cross-seeding between aggregation-prone proteins in neurodegenerationMovement Disorders.  29:306-306. 2014
2013 LRRK2 secretion in exosomes is regulated by 14-3-3Human Molecular Genetics.  22:4988-5000. 2013
2013 α-synuclein overexpression represses 14-3-3θ transcriptionJournal of Molecular Neuroscience.  51:1000-1009. 2013
2013 IPX066: a new intermediate-and extended-release carbidopa-levodopa formulation.Neurodegenerative Disease Management.  3:123-131. 2013
2013 Angiogenin in Parkinson Disease Models: Role of Akt Phosphorylation and Evaluation of AAV-Mediated Angiogenin Expression in MPTP Treated MicePLoS One.  8. 2013
2012 Functional analysis of VPS41-mediated neuroprotection in Caenorhabditis elegans and mammalian models of Parkinson's disease 2012
2011 14-3-3theta protects against neurotoxicity in a cellular parkinson's disease model through inhibition of the apoptotic factor BaxPLoS One.  6. 2011
2011 A neuroprotective role for angiogenin in models of Parkinson's diseaseJournal of Neurochemistry.  116:334-341. 2011
2011 Defects in very long chain fatty acid synthesis enhance alpha-synuclein toxicity in a yeast model of Parkinson's diseasePLoS One.  6. 2011
2010 Target validation: The Parkinson disease perspectiveDisease Models and Mechanisms.  3:259-262. 2010
2010 Differential neuroprotective effects of 14-3-3 proteins in models of Parkinson's diseaseCell Death and Disease.  1. 2010
2009 Targets for neuroprotection in Parkinson's disease 2009
2009 Racial differences in parkinson's disease medication use in the reasons for geographic and racial differences in stroke cohort: A cross-sectional studyNeuroepidemiology.  33:329-334. 2009
2008 Transcriptional dysregulation in a transgenic model of Parkinson diseaseNeurobiology of Disease.  29:515-528. 2008
2008 Lysosomal enzyme cathepsin D protects against alpha-synuclein aggregation and toxicity.Molecular Brain.  1:17. 2008
2000 Truncated and full-length TrkB receptors regulate distinct modes of dendritic growthNature Neuroscience.  3:342-349. 2000
1999 Subcellular localization of full-length and truncated Trk receptor isoforms in polarized neurons and epithelial cells 1999

Chapter

Year Title Altmetric
2017 Neurodegenerative Disorders: Why Do We Need New Therapies?.  1-16. 2017
2011 Neuroprotective Therapies for Parkinson’s disease 2011

Teaching Activities

  • GBSC720 - Journal Club 2 (Fall Term 2016)
  • GBSC720 - Journal Club 2 (Fall Term 2017)
  • GBSC720 - Journal Club 2 (Fall Term 2018)
  • MSTP794 - Translational Research Seminar (Fall Term 2018)
  • MSTP794 - Translational Research Seminar (Fall Term 2019)
  • MSTP794 - Translational Research Seminar (Fall Term 2020)
  • MSTP794 - Translational Research Seminar (Fall Term 2021)
  • MSTP794 - Translational Research Seminar (Fall Term 2022)
  • MSTP794 - Translational Research Seminar (Spring Term 2019)
  • MSTP794 - Translational Research Seminar (Spring Term 2020)
  • MSTP794 - Translational Research Seminar (Spring Term 2021)
  • MSTP794 - Translational Research Seminar (Spring Term 2022)
  • MSTP794 - Translational Research Seminar (Summer Term 2019)
  • MSTP794 - Translational Research Seminar (Summer Term 2020)
  • MSTP794 - Translational Research Seminar (Summer Term 2021)
  • MSTP794 - Translational Research Seminar (Summer Term 2022)
  • MSTP798 - MSTP Non-Dissertation Hours (Fall Term 2018)
  • MSTP798 - MSTP Non-Dissertation Hours (Fall Term 2019)
  • MSTP798 - MSTP Non-Dissertation Hours (Fall Term 2020)
  • MSTP798 - MSTP Non-Dissertation Hours (Fall Term 2021)
  • MSTP798 - MSTP Non-Dissertation Hours (Fall Term 2022)
  • MSTP798 - MSTP Non-Dissertation Hours (Spring Term 2019)
  • MSTP798 - MSTP Non-Dissertation Hours (Spring Term 2020)
  • MSTP798 - MSTP Non-Dissertation Hours (Spring Term 2021)
  • MSTP798 - MSTP Non-Dissertation Hours (Spring Term 2022)
  • MSTP798 - MSTP Non-Dissertation Hours (Summer Term 2019)
  • MSTP798 - MSTP Non-Dissertation Hours (Summer Term 2020)
  • MSTP798 - MSTP Non-Dissertation Hours (Summer Term 2021)
  • MSTP798 - MSTP Non-Dissertation Hours (Summer Term 2022)
  • MSTP799 - MSTP Dissertation Hours (Fall Term 2018)
  • MSTP799 - MSTP Dissertation Hours (Fall Term 2019)
  • MSTP799 - MSTP Dissertation Hours (Fall Term 2020)
  • MSTP799 - MSTP Dissertation Hours (Fall Term 2021)
  • MSTP799 - MSTP Dissertation Hours (Fall Term 2022)
  • MSTP799 - MSTP Dissertation Hours (Spring Term 2019)
  • MSTP799 - MSTP Dissertation Hours (Spring Term 2021)
  • MSTP799 - MSTP Dissertation Hours (Spring Term 2022)
  • MSTP799 - MSTP Dissertation Hours (Spring Term 2022)
  • MSTP799 - MSTP Dissertation Hours (Summer Term 2019)
  • MSTP799 - MSTP Dissertation Hours (Summer Term 2020)
  • MSTP799 - MSTP Dissertation Hours (Summer Term 2021)
  • MSTP799 - MSTP Dissertation Hours (Summer Term 2022)
  • NBL787 - Neurodegerative Dis Jrnl Club (Fall Term 2013)
  • NBL787 - Neurodegerative Dis Jrnl Club (Fall Term 2014)
  • NBL787 - Neurodegerative Dis Jrnl Club (Fall Term 2015)
  • PSDO700 - Pathway to Grant Submission (Spring Term 2020)
  • PSDO700 - Pathway to Grant Submission (Spring Term 2021)
  • PSDO700 - Pathway to Grant Submission (Spring Term 2022)
  • Education And Training

  • Massachusetts General Hospital, Residency
  • Massachusetts General Hospital, Postdoctoral Fellowship
  • Doctor of Medicine, Duke University 2001
  • Doctor of Philosophy in Neurobiology and Neurosciences, Duke University 2001
  • Full Name

  • Talene Yacoubian